Serum levels of sex hormone binding globulin (SHBG) are not predictive of prostate cancer diagnosis and aggressiveness: results from an Italian biopsy cohort.

PURPOSE To explore the association between serum levels of Sex Hormone Binding Globulin (SHBG) and the risk of developing prostate cancer (PCa) as well as high grade disease in men undergoing prostate biopsy. MATERIALS AND METHODS Between 2006 and 2012, we prospectively enrolled 740 patients with no history of PCa undergoing prostate biopsy. Before biopsy general data of the patient DRE, PSA and BMI were recorded. The risk of detecting cancer and high grade cancer was assessed as a function of SHBG using crude and adjusted logistic regressions. RESULTS Serum levels of SHBG were not associated with an increased risk of PCa or high grade disease. Age (OR 1.027 95% CI 1.003-1.052 p = 0.027), DRE (OR 3.391 95% CI 2.258-5.092 p = 0.000) and PSA (OR 1.078 95% CI 1.037-1.120 p = 0.000) were found to be independent predictors of prostate cancer risk. Age (OR 1.051 95% CI 1.009-1.095 p = 0.016), DRE (OR 2.519 95% CI 1.384-4.584 p = 0.000), BMI (OR 1.098 95% CI 1.011-1.193 p = 0.027) and PSA (OR 1.074 95% CI 1.014-1.137 p = 0.015) were found to be independent predictors of high grade disease. CONCLUSIONS In our cohort of patients, serum levels of SHBG are not predictive of PCa or high grade disease. According to our experience SHBG should not be considered a biomarker in PCa diagnosis neither a marker for high grade disease.

[1]  S. Freedland,et al.  Obesity and prostate cancer: weighing the evidence. , 2013, European urology.

[2]  W. Barry,et al.  Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy. , 2012, Urology.

[3]  A. Jemal,et al.  International variation in prostate cancer incidence and mortality rates. , 2012, European urology.

[4]  S. Freedland,et al.  The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  U. Capitanio,et al.  Circulating estradiol, but not testosterone, is a significant predictor of high‐grade prostate cancer in patients undergoing radical prostatectomy , 2011, Cancer.

[6]  S. Freedland,et al.  Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy , 2011, The Prostate.

[7]  U. Capitanio,et al.  Sex hormone‐binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy , 2011, BJU international.

[8]  M. Inoue,et al.  Plasma testosterone and sex hormone‐binding globulin concentrations and the risk of prostate cancer among Japanese men: A nested case‐control study , 2010, Cancer science.

[9]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[10]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[11]  M. Terris,et al.  Re: The Number of Cores Positive for High Grade Prostatic Intraepithelial Neoplasia on Initial Biopsy is Associated with Prostate Cancer on Second Biopsy , 2009 .

[12]  U. Capitanio,et al.  Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection. , 2009, Urology.

[13]  R. Miano,et al.  The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. , 2009, The Journal of urology.

[14]  S. Byun,et al.  Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer. , 2008, European urology.

[15]  R. Miano,et al.  Finasteride for prostatic disease: an updated and comprehensive review , 2008, Expert opinion on drug metabolism & toxicology.

[16]  S. Freedland,et al.  Obesity is a significant risk factor for prostate cancer at the time of biopsy. , 2008, Urology.

[17]  A. Roddam,et al.  Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. , 2008, Journal of the National Cancer Institute.

[18]  P. Stattin,et al.  Androgens and prostate cancer risk: A prospective study , 2007, The Prostate.

[19]  R. Hayes,et al.  Variant in Sex Hormone-Binding Globulin Gene and the Risk of Prostate Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[20]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[21]  G. Kramer,et al.  High‐grade prostate cancer is associated with low serum testosterone levels , 2001, The Prostate.

[22]  W. DeWolf,et al.  Is low serum free testosterone a marker for high grade prostate cancer? , 2000, The Journal of urology.

[23]  A. Reunanen,et al.  Serum testosterone and sex hormone‐binding globulin concentrations and the risk of prostate carcinoma , 1999, Cancer.

[24]  N. Weigel,et al.  Ligand-independent activation of steroid hormone receptors , 1998, Journal of Molecular Medicine.

[25]  M. Stampfer,et al.  Prospective study of sex hormone levels and risk of prostate cancer. , 1996, Journal of the National Cancer Institute.

[26]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. , 1941, CA: a cancer journal for clinicians.

[27]  R. Lombardo,et al.  Serum levels of 17-β-estradiol are not predictive of prostate cancer diagnosis and aggressiveness: results from an Italian biopsy cohort. , 2014, Urologic oncology.

[28]  G. Morgia,et al.  Molecular markers for prostatic cancer. , 2010, Frontiers in bioscience.

[29]  R. Pasquali,et al.  Effect of obesity and body fat distribution on sex hormones and insulin in men. , 1991, Metabolism: clinical and experimental.